These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38092371)

  • 61. Loss of expression of BAP1 predicts longer survival in mesothelioma.
    Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ
    Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MUC1 has prognostic significance in malignant peritoneal mesothelioma.
    Pillai K; Pourgholami MH; Chua TC; Morris DL
    Int J Biol Markers; 2013 Sep; 28(3):303-12. PubMed ID: 23828409
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
    Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
    Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
    Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
    J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 66. BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
    Erber R; Warth A; Muley T; Hartmann A; Herpel E; Agaimy A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):67-73. PubMed ID: 30640754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
    De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
    J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pleural mesothelioma.
    Porcel JM
    Med Clin (Barc); 2022 Sep; 159(5):240-247. PubMed ID: 35636988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
    Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
    Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
    Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
    J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series.
    Broggi G; Massimino M; Failla M; Filetti V; Rapisarda V; Ledda C; Lombardo C; Loreto C; Vigneri P; Caltabiano R
    Pathol Res Pract; 2024 Jul; 259():155350. PubMed ID: 38781764
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
    Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
    Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
    Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
    Cantini L; Pecci F; Murrone A; Tomasetti M; Copparoni C; Fiordoliva I; Morgese F; Rinaldi S; Mazzanti P; Rubini C; Cimadamore A; Barbisan F; Giampieri R; Scarpelli M; Santarelli L; Berardi R
    Lung Cancer; 2020 Aug; 146():318-326. PubMed ID: 32622302
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.